· Arijit Chakravarty
In the biotech/pharma industry, drug development projects hold the power to make or break companies and careers. It’s hard enough as it is to get a molecule to the finish line, but a tight market for funding can make that so much more difficult!
Read More →
17 October 2022 · Arijit Chakravarty
We’ve all heard the numbers - ten years, a billion dollars, and a 90% failure rate. Why is it so slow, expensive, and risky to take a drug candidate through the approval process?
Read More →
10 October 2022 · Arijit Chakravarty
A drug discovery program at its inception can feel like such a gamble. The biology is often still being understood, and it’s often unclear whether the chemistry will cooperate.
Read More →
27 September 2022 · Arijit Chakravarty
Model-based drug development offers a faster, more efficient way to identify promising medicines, assess clinical performance, and demonstrate safety and efficacy.
Read More →